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SIRT1 is an NAD-dependent deacetylase that regulates stress response pathways. By
deacetylating transcription factors and co-factors, SIRT1 modulates metabolism, inﬂamma-
tion, hypoxic responses, circadian rhythms, cell survival, and longevity. Since SIRT1 plays a
key role in regulating pathways involved in cardiovascular diseases and metabolic diseases
cancer, the regulation of SIRT1 has received intense scrutiny.The post-transcriptional regu-
lation of SIRT1 is mediated by two classes of molecules, RNA-binding proteins (RBPs) and
non-coding small RNAs. MicroRNAs (miRNAs) are short non-coding RNAs that regulate
target gene expression in a post-transcriptional manner. More than 16 miRNAs modulate
SIRT1 expression, including miR-34a. miR-34a induces colon cancer apoptosis through
SIRT1, and miR-34a also promotes senescence in endothelial cells via SIRT1. This review
describes the impact of miRNAs on SIRT1. The background of SIRT1 and miRNAs will be
summarized, followed by the mechanism by which several key miRNAs alter SIRT1 levels,
and how the RBP HuR regulates SIRT1. MicroRNA regulation of SIRT1 might affect a wide
variety of pathways in humans, from metabolic diseases such as diabetes to cardiovascular
diseases and cancer.
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SIRT1 OVERVIEW
Sir2 was originally identiﬁed as the silencing information regu-
lator 2 in S. cerevisiae (Kennedy et al., 1995). In yeast, Sir2 is
recognized as a regulator of lifespan (Kaeberlein et al., 1999).
Sir2 is a histone deacetylase (Imai et al., 2000), and it promotes
longevity by its deacetylase activity. The human orthologs of Sir2
include seven members, SIRT1-7. SIRT1 is a highly conserved
nicotinamide adenine dinucleotide (NAD)+-dependent protein
deacetylase, that regulates chromatin remodeling, stress responses,
DNA repair, insulin regulation, lifespan (Guarente and Picard,
2005). The diverse effects of SIRT1 reﬂect its ability to deacety-
late a variety of transcriptional factors, such as p53, forkhead box
O (FoxO),NF-κB, and peroxisome proliferators activated receptor
gamma coactivator-1α (PGC-1α; Brunet et al., 2004; Yeung et al.,
2004; Rodgers et al., 2005).
SIRT1 AND CANCER
SIRT1 plays an important role in cancer (Liu et al., 2009). SIRT1
expression is increased in human cancers such as prostate can-
cer, colon cancer, acute myeloid leukemia, and some skin can-
cers (Bradbury et al., 2005; Hida et al., 2007; Huffman et al.,
2007; Stunkel et al., 2007). SIRT1 might act as a tumor pro-
moter in these diseases by interacting with and inhibiting p53
(van Leeuwen and Lain, 2009). SIRT1 also represses expression of
tumor suppressor proteins and DNA repair proteins. But SIRT1
expression is decreased in other cancers, including ovarian can-
cer, glioblastoma, and bladder carcinoma (Deng, 2009). SIRT1
might serve as a tumor suppressor in these diseases by blocking
oncogenic pathways. For example, SIRT1 limits β-catenin sig-
naling in colon cancer, and in breast cancer BRCA1 signaling
interacts with the SIRT1 pathway (Mullan et al., 2006; Firestein
et al., 2008). Thus SIRT1 can serve as a tumor promoter or
tumor suppressor, depending on the oncogenic pathways speciﬁc
to particular tumors.
SIRT1 AND METABOLIC DISORDERS
SIRT1 also regulates metabolism and modulates metabolic dis-
eases like diabetes (Lee andKemper,2010).Cellular studies showed
that SIRT1 modulates fat accumulation, regulates mitochondrial
biogenesis, and activates fatty acid oxidation. Mouse studies have
revealed important physiological effects of SIRT1. SIRT1 affects
metabolism of mice during caloric restriction (Haigis and Guar-
ente, 2006). Transgenic mice over-expressing SIRT1 are protected
from some pathological conditions including insulin resistance
and glucose tolerance (Banks et al., 2008). Moreover, mice treated
with SRT1720, a speciﬁc synthetic activator of SIRT1, are pro-
tected from diet-induced obesity and insulin resistance (Feige
et al., 2008). Taken together, these in vivo results suggest that SIRT1
regulates mammalian metabolism.
SIRT1 also protects the host against obesity. SIRT1 transgenic
mice were protected from high-fat diet-induced obesity and liver
steatosis (Banks et al., 2008; Pﬂuger et al., 2008). Conversely SIRT1
heterozygous mice fed with high-fat diet gain body weight, exhibit
liver steatosis and inﬂammation in fat (Xu et al., 2010). These mice
data indicate that SIRT1 regulates systemic metabolism.
SIRT1 AND AGING
The physiological impact of SIRT1 upon aging inmammals is con-
troversial. The original proposal that SIRT1 regulates mammalian
aging came from two sources. Studies of the SIRT1 homolog Sir2
show that Sir2 prolongs longevity in yeast (Hekimi and Guarente,
2003). Additionally, prolongation of survival by caloric restric-
tion also increases SIRT1 activity (Bordone and Guarente, 2005).
Despite these tantalizing hints about the relation of SIRT1 and
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longevity, a conclusive link between the two has not yet been estab-
lished. For example,moderate expression of SIRT1 attenuates age-
dependent incidence of cardiac hypertrophy and dysfunction by
inducing resistance to oxidative stress in mice heart; however high
level of SIRT1 increases heart dysfunction (Alcendor et al., 2007).
SIRT1 AND THE VASCULATURE
SIRT1 controls angiogenesis, in part by regulating key transcrip-
tion factors and radicals in response to stress (Potente and Dim-
meler, 2008). FoxO1 and FoxO3a are transcription factors in
endothelial cells that inhibit endothelial cells migration and tube
formation (Potente et al., 2005). Loss of SIRT1 increases acety-
lation of FoxO1, a negative regulator of angiogenesis, thereby
limiting angiogenic activity in endothelial cells (Potente et al.,
2007). Furthermore, SIRT1 also increases expression of Kruppel-
like factor 2 (KLF2), a transcription factor in endothelial cells that
activates expression of vasculoprotective genes (Gracia-Sancho
et al., 2010). Thus SIRT1 controls transcription factors such as
FOXO and KLF2 that are crucial regulators of endothelial cells
(Figure 1).
Two interesting studies indicate the link between SIRT1 and
endothelial function. First, SIRT1 regulates eNOS and NO synthe-
sis. Calorie restriction induces SIRT1 and eNOS expression inmale
mice, and this effect is attenuated in eNOS knockout mice (Nisoli
et al., 2005). Second, SIRT1 deacetylates and activates endothe-
lial nitric oxide synthase (eNOS; Mattagajasingh et al., 2007).
Since eNOS synthesizes NO, which maintains vascular homeosta-
sis, these data support the beneﬁcial role of SIRT1 in the vascular
endothelium.
Finally, SIRT1 protects smooth muscle by decreasing
angiotensin I signaling: SIRT1 decreases expression of the
angiotensin receptor, which in turn limits reactive oxygen species
FIGURE 1 |The role of SIRT1 in vasculature. SIRT1 mediates important
cellular processes in cardiovascular systems. Calorie restriction and
resveratrol enhance SIRT1 expression and activity. SIRT1 modulates cellular
responses in cardiovascular systems by regulating the activity of several
transcription factors.
(Li et al., 2011). Thus SIRT1 acts within endothelial cells and
smooth muscle cells to protect the vasculature.
BACKGROUND OF microRNAs
MicroRNAs (miRNAs) are non-coding ∼23 nt RNAs that control
gene expression by suppressing translation or reducing stability
of their target mRNAs (Bartel, 2004). MiRNAs modulate a vari-
ety of important functions including proliferation, differentiation,
apoptosis, and senescence in animals and plants (Ambros, 2004;
He and Hannon, 2004; Croce, 2008).
The biogenesis of miRNAs consists of several processing steps.
Most miRNAs are transcribed into long primary transcripts (pri-
miRNAs) by RNA polymerase II. Pri-miRNAs are cleaved into
stem–loop structural miRNA precursors (pre-miRNAs) by the
microprocessor complex, composed of RNase III enzymes Drosha
and DGCR8. These∼70 nt pre-miRNAs are exported to the cyto-
plasm by exportin-5 and cleaved by RNase III enzyme Dicer to
generate duplex mature miRNAs. One or both single strands of
mature miRNAs are incorporated into Argonaute (Ago2) in a
miRNA–protein complex (RISC), which binds to the 3′ untrans-
lated region (3′UTR) of target mRNAs. The binding of mature
miRNA to the 3′UTR of target mRNAs depends on the interac-
tion of the 6- to 8-nt seed sequence at the 5′ ends of miRNA, and
miRNA response elements in the target mRNA.
Several algorithms are available to predict potential target genes
of miRNAs (Sethupathy et al., 2006; Hofacker, 2007). These meth-
ods are incorporated into miRNA target prediction programs on
line such as Targetscan1, miRanda2, and PicTar3. The algorithms
are based upon seed sequence of mRNA, and identify hundreds of
1www.targetscan.org
2www.microrna.org
3pictar.mdc-berlin.de
FIGURE 2 | Regulation of SIRT1 by miRNAs. Schema shows that miRNAs
regulate SIRT1 expression and function directly or through HuR. miR-22,
miR-34, miR-143/145, miR-195, miR-199a, and miR-217 are expressed well
in vascular tissues and control SIRT1 protein. SIRT1 is regulated by more
than 15 miRNAs. miR-16, miR-125a, and miR-519 decrease HuR
expression. In contrast, HuR controls the post-transcriptional regulation of
miRNAs such as miR-122 and let-7. Moreover HuR binds to the 3′UTR of
SIRT1 and changes SIRT1 mRNA stability.
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potential target genes. Using these methods, several miRNA have
been predicted to regulate SIRT1, as discussed below.
REGULATION OF SIRT1
Several endogenous and exogenous regulators of SIRT1 have been
identiﬁed. The protein encoded by deleted in breast cancer 1
(DBC1) is a natural inhibitor of SIRT1 activity. DBC1 forms a
complex with SIRT1 to act as a tumor suppressor, but knockout
of DBC1 increases SIRT1 activity, promoting tumorigenesis (Kim
et al., 2008; Zhao et al., 2008). Resveratrol was the small mole-
cule ﬁrst identiﬁed to regulate SIRT1 activity and to extend life
span. After the effect of resveratrol upon SIRT1 was characterized,
high throughput screening was used to ﬁnd other small molecule
activators of SIRT. For example, SRT1720 was found to improve
insulin sensitivity and decrease blood glucose levels (Milne et al.,
2007), although its effects on SIRT1 are still questionable (Pacholec
et al., 2010).
Under environmental stress, cells respond by activating sets
of genes to maintain homeostasis. Although the role of SIRT1
in mediating stress responses is well established, the factors that
control SIRT1 expression are less well understood. The fol-
lowing section reviews recent studies demonstrating the post-
transcriptional regulation of SIRT1 by miRNAs and RNA-binding
proteins (RBPs).
miRNAs REGULATION OF SIRT1 (Figure 2)
More than 16 miRNAs regulate SIRT1 expression and activity
(Table 2). Among these miRNAs, miR-34a has been the most
studied (Table 1).
miR-34a AND SENESCENCE OF CANCER CELLS AND ENDOTHELIAL
CELLS
The ﬁrst identiﬁed miRNA that regulates SIRT1 is miR-34a
(Yamakuchi et al., 2008). miR-34a was discovered as a tumor
Table 1 | miR-34a targets SIRT1.
Tumor Reference
mIR-34ATARGETS SIRT1 IN CANCER CELLS
Pancreatic cancer Pramanik et al. (2011)
Colorectal cancer Akao et al. (2011)
Prostate cancer Kojima et al. (2010)
Brain cancer Luan et al. (2010)
Liver cancer Pogribny et al. (2009)
Prostate cancer Fujita et al. (2008)
Colon cancer Yamakuchi et al. (2008)
Cells Reference
mIR-34ATARGETS SIRT1 IN NORMAL CELLS
Neural differentiation Aranha et al. (2011)
Liver metabolism Lee et al. (2010)
Endothelial cell senescence Ito et al. (2010)
Endothelial progenitor cell senescence Zhao et al. (2010)
miR-34a regulates SIRT1 in brain, liver, and endothelial cells, as well as in various
cancer cells.
suppressor gene in neuroblastoma (Welch et al., 2007). Deletion of
chromosome 1p where miR-34a is located on was found in 30% of
advanced stage neuroblastomas (Versteeg et al., 1995; Calin et al.,
2004). Since these initial reports, low levels of miR-34a expres-
sion were reported in prostate cancer, hepatocellular carcinoma,
chronic lymphocytic leukemia (CLL), colon cancer, and ovarian
cancer (Bommer et al., 2007; Chang et al., 2007; Tazawa et al., 2007;
Fujita et al., 2008; Li et al., 2009; Corney et al., 2010).
One mechanism by which miR-34a expression decreases in
cancers is due to aberrant CpG methylation of the promoter of
miR-34a (Lodygin et al., 2008). Another potential molecule that
alters miR-34a expression in cancer is p53. More than half of all
human cancers have mutations in p53 tumor suppressor gene. p53
directly increasesmiR-34a expression (Bommer et al., 2007;Chang
et al., 2007; Tazawa et al., 2007; Fujita et al., 2008; Li et al., 2009;
Corney et al., 2010).
Reduced expression of miR-34a alters cellular function in can-
cer cells. Ectopic expression of miR-34a induced cell cycle arrest in
theG1 phase and apoptosis in several cancer cells andmany poten-
tial targets of miR-34a have been identiﬁed (Bommer et al., 2007;
Chang et al., 2007; He et al., 2007; Tarasov et al., 2007). However,
the precise molecular targets of miR-34a were unknown.
We discovered that miR-34a regulates SIRT1, using a colon can-
cer cell line, HCT116 as a model system. The ﬁrst clue to SIRT1
as a target of miR-34a came from prediction algorithms. The next
evidence for a link between miR-34a and SIRT1 came from exper-
iments in which treatment of HCT116 with adriamycin increased
p53 protein, induced miR-34a expression, and decreased SIRT1.
(However, adriamycin did not alter the expression of miR-34a and
SIRT1 in HCT116 cells that lack p53). These results suggested
that p53 induced miR-34a expression, which decreased SIRT1
protein expression. miR-34a inhibition of SIRT1 increased acety-
lated p53 and expression of p53 transcriptional targets, p21 and
PUMA, which regulate the cell cycle and apoptosis. Since this ini-
tial report, SIRT1 regulation by miR-34a has been reported in
colorectal cancer, prostate cancer, hepatocarcinoma, glioma, and
pancreatic cancer (Fujita et al., 2008; Pogribny et al., 2009; Kojima
et al., 2010; Luan et al., 2010; Akao et al., 2011; Pramanik et al.,
2011).
In the cardiovascular system, miR-34a also plays an important
role in regulating cellular senescence and angiogenesis through
SIRT1. We have shown that miR-34a induces senescence and
cell cycle arrest in endothelial cells. Overexpression of miR-
34a inhibits SIRT1 expression and endothelial senescence (Ito
et al., 2010). miR-34a expression in heart and spleen are higher
in older mice than those in younger mice. Conversely SIRT1
expression decreased with age. Our data suggested that miR-
34a is a direct regulator of endothelial senescence. miR-34a also
inhibits endothelial progenitor cells (EPC) mediated angiogenesis
by induction of senescence (Zhao et al., 2010). miR-34a also mod-
ulates downstream targets of SIRT1 such as FoxO1, enhancing
senescence. In murine ESCs, miR-34a targets SIRT1 and con-
tributes to pluripotency of ESCs. Thus SIRT1 plays an important
role in the cardiovascular system, and miR-34a in turn modulates
SIRT1 expression.
miR-34a also inﬂuences cellular metabolism through its
effects upon SIRT1. SIRT1 directly interacts with PGC-1α and
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Table 2 | A list of miRNAs targeting SIRT1.
miRNAs regulating SIRT1 Tissue/cells/diseases Regulation/function Reference
miR-449a Cancer cell lines Inhibition of growth, apoptosis Lizé et al. (2010)
miR-449 Gastric cancer Apoptosis, senescence Bou Kheir et al. (2011)
miR-22 Fibroblast and cancer Inhibition of growth and metastasis, senescence Xu et al. (2011)
miR-200a Mammary epithelial cell Epithelial to mesenchymal transition (EMT) Eades et al. (2011)
miR-143/145 Pancreatic cancer Growth arrest, apoptosis Pramanik et al. (2011)
miR-217 Endothelial cells Senescence Menghini et al. (2009)
miR-195 Cardiomyocyte Palmitate induced apoptosis Zhu et al. (2011)
miR-199a Heart Ischemia Rane et al. (2009)
miR-132 Adipocyte Stress-induced chemokine production Strum et al. (2009)
miR-181c, miR-9 Alzheimer disease Down-regulated by amyloid-β (Aβ) Schonrock et al. (2012)
miR-9 Pancreatic β-cell Insulin secretion Ramachandran et al. (2011)
miR-93 Liver Senescence Li et al. (2011)
miR-181a/b, miR-9, miR-204,
miR-199b, miR-135a
Mouse ES cell Differentiation Saunders et al. (2010)
miR-100, miR-137 Mouse ES cell Differentiation Tarantino et al. (2010)
miRNAs that regulates SIRT1 expression have diverse functions in different cells and tissues.
deacetylates PGC-1α, suggesting that SIRT1 maintains metabolic
homeostasis by modulating the activity of PGC-1α (Nemoto et al.,
2005). SIRT1 also suppresses a key adipogenic transcription factor,
PPARγ, and promotes fatmobilization inwhite adipocytes (Picard
et al., 2004). The liver is a key metabolic organ that regulates lipid
metabolism and glucose homeostasis. Hepatocyte-speciﬁc dele-
tion of SIRT1 impairs PPARα signaling and fatty acid β-oxidation
(Purushotham et al., 2009). In addition, liver-speciﬁc knockout of
SIRT1 leads to hepatic inﬂammation and endoplasmic reticulum
(ER) stress in the liver upon high-fat diet feeding. In hepato-
cyte, miR-34a regulates SIRT1. Farnesoid X receptor (FXR), one
of the key regulatory factors in liver metabolism, inhibits miR-
34a in HepG2 cells and hepatocyte-speciﬁc knockout of FXR
increasesmiR-34a expression in liver. In fatty livers of diet-induced
obese mice and ob/ob mice, the level of miR-34a is elevated and
SIRT1 is decreased (Lee et al., 2010). In pancreas, miR-34a over-
expression inhibits insulin secretion (Lovis et al., 2008). These
studies suggested that miR-34a strongly affects glucose and insulin
homeostasis through SIRT1.
miR-217 AND ENDOTHELIAL SENESCENCE
Computer algorithms predict a set of miRNA that regulate
SIRT1 (Table 2), and many of these have been veriﬁed in cells.
A miRNA proﬁling study revealed that miR-217 was signiﬁ-
cantly upregulated in old human umbilical vein endothelial cells
(HUVEC; PDL44) compared to young endothelial cells (PDL8;
Menghini et al., 2009). Computational target prediction identi-
ﬁed homology between miR-217 and 3′UTR of human SIRT1
mRNA. Overexpression of miR-217 suppresses SIRT1 expres-
sion in young endothelial cells. In contrast, inhibition of miR-
217 increased SIRT1 expression and promoted cellular senes-
cence in older HUVEC. Alteration of miR-217 controls SIRT1
level, which deacetylates FoxO1. Conﬁrming these in vitro stud-
ies, miR-217 level is negatively associated with SIRT1 expres-
sion in human atherosclerotic plaque from patients underwent
carotid endarterectomy. These results suggest that miR-217 plays
an important role in senescence during the development of
atherosclerosis.
miR-195 AND miR-199a AND CARDIAC METABOLISM
In cardiomyocytes, SIRT1 is controlled by miR-195. The free fatty
acid palmitate, upregulates miR-195 expression which inhibits
SIRT1 and promotes apoptosis (Zhu et al., 2011). Another cardiac
miRNA, miR-199a, limits expression of both SIRT1 and HIF-1α
(Rane et al., 2009). Hypoxia or cardiac ischemia decreases miR-
199a, permitting an increase in SIRT1 in cardiac myocytes. SIRT1
in turn downregulates prolyl hydroxylase 2 (PHD2), which sta-
bilizes HIF-1α and hypoxia signaling. Thus miR-199 increases
HIF-1α in two ways: ﬁrst by regulating HIF-1α directly, second
by a SIRT1–PHD2–HIF-1 pathway.
miR-9 AND miR-132 AND GLUCOSE METABOLISM
TwomiRNAs control SIRT1 in pancreas and adipose tissue, critical
organs that regulate glucose metabolism. One miRNA is miR-9,
which modulates SIRT1 level in pancreatic β-cells (Ramachan-
dran et al., 2011). Previous studies showed that SIRT1 affects
insulin secretion by downregulation of UCP2 (Bordone et al.,
2006). SIRT1 conditional transgenic mice (BESTO mice) exhibit
a signiﬁcant alteration of insulin secretion in response to glu-
cose uptake, indicating a critical role of SIRT1 in the control
of insulin secretion (Moynihan et al., 2005). Ramachandran et
al. showed that glucose-stimulated insulin secretion is accom-
panied by changes in miR-9, which is mediated by SIRT1. In
adipocytes, miR-132 affects SIRT1 regulation. Adipose tissue
secretes a series of pro-inﬂammatory mediators that contribute
to metabolic disorders. Serum deprivation induces the produc-
tion of chemokines such as IL-8 and MCP-1 in adipocytes.
In low serum condition, miR-132 expression is upregulated.
Overexpression of miR-132 decreases SIRT1 expression, which
blocks deacetylation of p65 NFκB, causing induction of IL-8 and
MCP-1.
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miR-200a, miR-449, AND miR-22 AND TUMORIGENESIS
In cancer cells, senescence inhibits proliferation and induces apop-
tosis. Since SIRT1 is a major protein that regulates cellular senes-
cence, miRNAs targeting SIRT1 have the potential to control
cancer progression.
The miR-200 family is important regulator of tumor progres-
sion and metastasis (Brabletz and Brabletz, 2010). The miR-200
family consist of two clusters; (1) miR-200b, miR-200a, and miR-
429, and (2) miR-200c and miR-141. Loss of miR-200a expression
is associated with epithelial to mesenchymal transformation, in
part via SIRT1 upregulation in breast cancer (Eades et al., 2011).
miR-449 expression is decreased in Gastrin knockout mice, that
are achlorhydric and tend to develop antral hyperplasia and gastric
adenomas later (Bou Kheir et al., 2011). In human gastric cancers,
miR-449 level is also down-regulated. One of miR-449 target is
SIRT1, although miR-449 has a number of other targets of cell
cycle related genes. Since the seed sequence of miR-449 is the same
as that of miR-34a, target genes of miR-449 and miR-34a over-
lap. Increased miR-449 inhibits cellular proliferation and induces
senescence in gastric cancer cell line, SNU638. Xu et al. (2011)
performed miRNA proﬁling of senescent ﬁbroblasts, showing that
several miRNAs including miR-22, miR-34a, and miR-125a-5p
are involved in cellular senescence in human diploid ﬁbroblasts.
Among them, miR-22 is highly expressed in senescent ﬁbroblast,
but relatively lower in cancers. Overexpression of miR-22 sup-
presses the proliferation in ﬁbroblasts and human breast cancer
cell line MCF7. SIRT1 is identiﬁed as a direct target of miR-22
as well as CDK6 and Sp1. Moreover synthetic miR-22 delivery
inhibits breast tumor growth and metastasis in mice model of
breast cancer. Tumor over-expressing miR-22 shows high number
of senescent tumor cells.
These miRNAs described above are examples of tumor sup-
pressor miRNAs targeting SIRT1. However, the role of SIRT1 in
tumorigenesis is complex (Deng, 2009). Some studies show that
SIRT1 acts as a tumor suppressor protein. Mice that are dou-
ble heterozygous for SIRT1 and p53 (Sirt1+/−;p53+/−) develop
tumors inmultiple tissues such as primarily sarcomas, lymphomas,
teratomas, and carcinomas (Wang et al., 2008). When SIRT1
was activated by resveratrol, the frequency of tumorigenesis was
reduced. Another study showed that SIRT1 is a tumor promoter.
The interaction of SIRT1 and p53 leads to deacetylation of p53
(Lys382 residue). SIRT1 overexpression inhibits p53 dependent
cell cycle arrest and apoptosis (Luo et al., 2001; Vaziri et al., 2001).
In contrast, suppression of SIRT1 activity increases p53 depen-
dent transcriptional activity (Lain et al., 2008). These data indicate
that SIRT1 deacetylates and inactivates p53 function, enhancing
tumorigenesis. Thus the effects of SIRT1 upon tumors depend in
part upon the type of tumor and the p53 status of the tumor.
SIRT1 REGULATION OF miRNAs
SIRT1 regulates many transcriptional factors by their deacetyla-
tion, as described above. Therefore it is likely that SIRT1 controls
expression of miRNAs by activating their transcriptional factors.
One example of this is SIRT1 regulation of a brain speciﬁcmiRNA,
miR-134 (Gao et al., 2010). SIRT1 modulates synaptic plastic-
ity and memory formation via a miRNA-mediated mechanism.
SIRT1 suppresses miR-134 transcription in normal condition by
a repressor complex containing transcription factor YY1. Loss
of SIRT1 activity results in the increase of miR-134, which
downregulates CREB and BDNF expression, impairing synaptic
plasticity.
A number of miRNAs regulate SIRT1 expression and activity.
Some of these miRNAs are controlled by stress-induced tran-
scriptional factors. As shown in miR-34a, p53 upregulates miR-
34a expression. SIRT1, the target of miR-34a, deacetylates and
destabilize p53, decreasing p53 activity (Luo et al., 2001; Vaziri
et al., 2001). Therefore p53 increases miR-34a expression, then
downregulates SIRT1 level, which increases p53 expression and
activity. The increase of p53 produces more miR-34a. This is a
positive loop, p53–miR-34a–SIRT1 (Yamakuchi and Lowenstein,
2009). This study of miR-134 indicates the possibility that SIRT1
alters some miRNAs expression, suggesting that another inter-
esting loop: miRNA–SIRT1–miRNA. These studies suggest the
complexities of the miRNA–SIRT1 network.
ADDITIONAL PATHWAYS FOR POST-TRANSCRIPTIONAL
REGULATION OF SIRT1: RNA-BINDING PROTEINS
The RBP HuR (Hu antigen R, ELAVL1) regulates SIRT1 in a post-
transcriptional manner. HuR is a member of ELAVL1family of
RBPs (Hinman and Lou, 2008; Katsanou et al., 2009; Papadaki
et al., 2009). HuR binds to AU-rich elements (AREs) in the 3′UTR
of mRNAs (Caput et al., 1986; Shaw and Kamen, 1986; Szabo
et al., 1991). HuR controls the stability of thousands of mRNA,
including SIRT1.
HuR regulates SIRT1 expression by direct and indirect path-
ways. HuR directly binds to ARE in the SIRT1 mRNA, which
stabilizes SIRT1 (Abdelmohsen et al., 2007).WhenHuR is silenced,
SIRT1 mRNA levels are decreased; in contrast, overexpression
of HuR increases SIRT1 mRNA. Interestingly, senescent ﬁbrob-
lasts exhibit low level of SIRT1 and HuR compared to young
ﬁbroblasts. One possible explanation is that repression of HuR
by cellular senescence reduces SIRT1 expression in ﬁbroblasts. In
fact, knockdown of HuR decreases the proliferation rate. Under
oxidative stress, HuR dissociated from the SIRT1 mRNA, caus-
ing its rapid degradation. Furthermore the checkpoint kinase 2
(Chk2) phosphorylates HuR, which inhibits the binding of SIRT1
and HuR. Three phosphorylation sites (two serine residues and
one threonine residue) by Chk2 are identiﬁed on HuR. These
results clearly suggest that RBP, HuR, controls the alteration of
SIRT1 expression.
In addition to HuR binding directly to SIRT1 mRNA,HuR also
regulates SIRT1 expression through indirect pathways that involve
microRNA.Theproﬁle of microRNAexpression is altered in senes-
cent ﬁbroblasts, with older cells expressing higher levels of sev-
eral microRNA species, including miR-519 (Marasa et al., 2010).
miR-519 inhibits HuR levels, which leads to decreased SIRT1
expression and senescence. Others have conﬁrmed that miR-519
represses HuR translation, thereby altering HuR regulation of
mRNA stability (Abdelmohsen et al., 2008).
SUMMARY
SIRT1 signaling is complex, and controversies about the role
of SIRT1 in longevity and cancer persist. Does SIRT1 really
extend lifespan?Does SIRT1 accelerate or slow cancer progression?
www.frontiersin.org March 2012 | Volume 3 | Article 68 | 5
Yamakuchi SIRT1 and microRNA
Regulation of SIRT1 adds to its complexity. Two major pathways
for post-transcriptional regulations of SIRT1 exist, RBPs and miR-
NAs. A discrete set of miRNAs regulates SIRT1 expression, and
different miRNA regulate SIRT1 in a cell speciﬁc manner. A major
regulator of SIRT1 is miR-34a, which suppresses SIRT1 expres-
sion in speciﬁc tissues and cancers, including colon cancer. The
RBP HuR is also involved in regulation of SIRT1 expression. The
interaction between HuR and miRNAs is interesting and is an
important area of future study.
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